Showing results (381-390 of 415) with videos related to
Sort By:
Pageof 42
Nature Medicine|June 3, 2024
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL studyFranck Morschhauser, Saurabh Dahiya, M Lia Palomba, et al.American Journal of Hematology|June 6, 2015
Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohortAndrew M Evens, Jennifer A Kanakry, Laurie H Sehn, et al.Lancet (London, England)|February 15, 2026
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 studyM Lia Palomba, Stephen J Schuster, Reem Karmali, et al.Journal of the National Comprehensive Cancer Network : JNCCN|February 6, 2020
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in OncologyWilliam G Wierda, John C Byrd, Jeremy S Abramson, et al.Neuro-Oncology|July 4, 2023
Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cellsPhilipp Karschnia, Isabel C Arrillaga-Romany, April Eichler, et al.Oncoimmunology|August 7, 2024
DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphomaZijun Y Xu-Monette, Cancan Luo, Li Yu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2019
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303Nancy L Bartlett, Wyndham H Wilson, Sin-Ho Jung, et al.The New England Journal of Medicine|December 4, 2018
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLLJennifer A Woyach, Amy S Ruppert, Nyla A Heerema, et al.Blood|September 2, 2020
Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphomaGabriel K Griffin, Jason L Weirather, Margaretha G M Roemer, et al.Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2024
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyWilliam G Wierda, Jennifer Brown, Jeremy S Abramson, et al.Pageof 42